Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The ANKH ΔE490Mutation in Calcium Pyrophosphate Dihydrate Crystal Deposition Disease (CPPDD) affects tissue non-specific Alkaline Phosphatase (TNAP) activities.

Wang J, Tsui HW, Beier F, Pritzker KP, Inman RD, Tsui FW.

Open Rheumatol J. 2008;2:23-30. doi: 10.2174/1874312900802010023. Epub 2008 Apr 10.

2.

The CPPDD-associated ANKH M48T mutation interrupts the interaction of ANKH with the sodium/phosphate cotransporter PiT-1.

Wang J, Tsui HW, Beier F, Tsui FW.

J Rheumatol. 2009 Jun;36(6):1265-72. doi: 10.3899/jrheum.081118. Epub 2009 Apr 15.

PMID:
19369455
4.

Familial calcium pyrophosphate dihydrate deposition disease and the ANKH gene.

Williams CJ.

Curr Opin Rheumatol. 2003 May;15(3):326-31. Review.

PMID:
12707589
5.

The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease.

Netter P, Bardin T, Bianchi A, Richette P, Loeuille D.

Joint Bone Spine. 2004 Sep;71(5):365-8. Review.

PMID:
15474385
6.

Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH.

Williams CJ, Zhang Y, Timms A, Bonavita G, Caeiro F, Broxholme J, Cuthbertson J, Jones Y, Marchegiani R, Reginato A, Russell RG, Wordsworth BP, Carr AJ, Brown MA.

Am J Hum Genet. 2002 Oct;71(4):985-91. Epub 2002 Sep 17.

7.

Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease.

Williams CJ, Pendleton A, Bonavita G, Reginato AJ, Hughes AE, Peariso S, Doherty M, McCarty DJ, Ryan LM.

Arthritis Rheum. 2003 Sep;48(9):2627-31.

9.

Inhibition of alkaline phosphatase by cysteine: implications for calcium pyrophosphate dihydrate crystal deposition disease.

So PP, Tsui FW, Vieth R, Tupy JH, Pritzker KP.

J Rheumatol. 2007 Jun;34(6):1313-22. Epub 2007 May 15.

PMID:
17516619
10.

Microcytosis in ank/ank mice and the role of ANKH in promoting erythroid differentiation.

Wang J, Wang C, Tsui HW, Las Heras F, Cheng EY, Iscove NN, Chiu B, Inman RD, Pritzker KP, Tsui FW.

Exp Cell Res. 2007 Dec 10;313(20):4120-9. Epub 2007 Sep 20.

PMID:
17950726
11.

The role of ANKH in pathologic mineralization of cartilage.

Williams CJ.

Curr Opin Rheumatol. 2016 Mar;28(2):145-51. doi: 10.1097/BOR.0000000000000247. Review.

PMID:
26599446
12.

Mercaptopyruvate inhibits tissue-nonspecific alkaline phosphatase and calcium pyrophosphate dihydrate crystal dissolution.

Kannampuzha JV, Tupy JH, Pritzker KP.

J Rheumatol. 2009 Dec;36(12):2758-65. doi: 10.3899/jrheum.090098. Epub 2009 Nov 2.

PMID:
19884277
13.

The association between ANKH promoter polymorphism and chondrocalcinosis is independent of age and osteoarthritis: results of a case-control study.

Abhishek A, Doherty S, Maciewicz R, Muir K, Zhang W, Doherty M, Valdes AM.

Arthritis Res Ther. 2014 Jan 27;16(1):R25. doi: 10.1186/ar4453.

14.

Cuff tear arthropathy: evidence of functional variation in pyrophosphate metabolism genes.

Peach CA, Zhang Y, Dunford JE, Brown MA, Carr AJ.

Clin Orthop Relat Res. 2007 Sep;462:67-72.

PMID:
17563703
15.

Genetics of chondrocalcinosis.

Zaka R, Williams CJ.

Osteoarthritis Cartilage. 2005 Sep;13(9):745-50. Review.

16.

Pathophysiology of articular chondrocalcinosis--role of ANKH.

Abhishek A, Doherty M.

Nat Rev Rheumatol. 2011 Feb;7(2):96-104. doi: 10.1038/nrrheum.2010.182. Epub 2010 Nov 23. Review.

PMID:
21102543
17.
18.
19.

ANKH variants associated with ankylosing spondylitis: gender differences.

Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW.

Arthritis Res Ther. 2005;7(3):R513-25. Epub 2005 Feb 25.

20.

Genetics and mechanisms of crystal deposition in calcium pyrophosphate deposition disease.

Tsui FW.

Curr Rheumatol Rep. 2012 Apr;14(2):155-60. doi: 10.1007/s11926-011-0230-6. Review.

PMID:
22198832

Supplemental Content

Support Center